Corbus Pharmaceuticals Holdings Inc
Change company Symbol lookup
Select an option...
CRBP Corbus Pharmaceuticals Holdings Inc
PTI Proteostasis Therapeutics Inc
CALB California BanCorp
$NOPM2 Refinitiv Norway Metal & Mining Inde
EBAY eBay Inc
PTON Peloton Interactive Inc
GO Grocery Outlet Holding Corp
NUE Nucor Corp
SJM J M Smucker Co
KR Kroger Co
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Postmarket

Last Trade
Delayed
$1.20
-0.02 (-1.64%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$1.22
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
1.26
Day's Low
1.18
Volume
(Light)
Volume:
3,095,669

10-day average volume:
4,789,899
3,095,669

Tesla recalls older Model S, Model X vehicles in China: report

12:25 pm ET October 23, 2020 (MarketWatch)
Print

Tesla Inc. (TSLA) is recalling about 30,000 older, U.S.-made Model S and Model X vehicles in China due to suspension problems, Bloomberg reported (https://www.bloomberg.com/news/articles/2020-10-23/tesla-is-recalling-about-30-000-imported-vehicles-in-china?utm_medium=social&utm_source=twitter&utm_campaign=socialflow-organic&utm_content=business&cmpid=socialflow-twitter-business&sref=Oeyjq8by) Friday. The vehicles were made between Sept. 17, 2013, and Jan. 15, 2018, Bloomberg said, citing a statement from Chinese authorities. A Tesla representative in China declined to comment, Bloomberg said. China is the linchpin of Tesla's expansion plans, and the company said this week it had increased Model 3 production capacity at its Shanghai factory to 250,000 vehicles a year. It also cut the Model 3 price in China to make it the cheapest premium mid-size sedan in that country, and added a third shift at the China factory. Tesla on Wednesday reported better-than-expected third-quarter (http://www.marketwatch.com/story/tesla-stock-jumps-after-companys-q3-profit-sales-beat-expectations-11603311412)adjusted profit and sales, and the stock surged. The shares gave back some of those gains on Friday and were down around 6% for the week. For the year, the stock is up 391%, compared with an advance around 7% for the S&P 500 index.

-Claudia Assis; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 23, 2020 12:25 ET (16:25 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.